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Abstract
Introduction: Despite experimental evidence, clinical demonstration of acute state of oxidative stress and
inflammation during post-cardiac arrest syndrome is lacking. Plasma level of thioredoxin (TRX), a redox-active
protein induced under conditions of oxidative stress and inflammation, is increased in various critical care
conditions. We determined plasma TRX concentrations after cardiac arrest and assessed relationships with severity
and outcome.
Methods: Retrospective study of consecutive patients admitted to a single academic intensive care unit (ICU) for
out-of-hospital cardiac arrest (between July 2006 and March 2008). Plasma levels of TRX were measured at
admission, day (D) 1, 2 and 3.
Results: Of 176 patients included, median TRX values measured in ICU survivors and non-survivors were, respectively:
22 ng/mL (7.8 to 77) vs. 72.4 (21.9 to 117.9) at admission (P < 0.001); 5.9 (3.5 to 25.5) vs. 23.2 (5.8 to 81.4) at D1 (P =
0.003); 10.8 (3.6 to 50.8) vs. 11.7 (4.5 to 66.4) at D2 (P = 0.22); and 16.7 (5.3 to 68.3) vs. 17 (4.3 to 62.9) at D3 (P = 0.96).
Patients dying within 24 hours had significantly (P < 0.001) higher TRX levels (118.6 ng/mL (94.8 to 280)) than those
who died after 24 hours or survived (50.8 (13.9 to 95.7) and 22 (7.8 to 77)). The area under the ROC curve to predict
early death was 0.84 (0.76 to 0.91).
TRX levels on admission were significantly correlated with ‘low-flow’ duration (P = 0.003), sequential organ failure
assessment (SOFA) score (P < 0.001), and blood lactate concentration (P < 0.001), but not with ‘no-flow’ duration or
simplified acute physiology score (SAPS) II score. TRX levels and admission arterial pO2 correlated negatively (r = -0.17,
P = 0.03). Finally, cardiac arrest with cardiac etiology exhibited lower levels of TRX than in cases of extra-cardiac cause
(46 ng/mL (11 to 104) vs. 68 (42 to 137), P = 0.01).
Conclusions: Our data show for the first time that TRX levels were elevated early following cardiac arrest, suggestive of
oxidative stress and inflammation occurring with this condition. Highest values were found in the most severe patients.
TRX could be a useful tool for further exploration and comprehension of post-cardiac arrest syndrome.
Introduction
Shock and intractable multi-organ failure are the main
causes of death after successfully resuscitated cardiac
arrest (CA) [1]. Whilst cessation and reduction of blood
flow are the patent mechanisms of organ dysfunction,
the pathophysiology of post-cardiac arrest syndrome is
complex and remains only partially understood [2]. Ische-
mia/reperfusion and non-specific acute activation of the
inflammatory response are thought to contribute to tissular
and cellular abnormalities [3]. Uncontrolled inflammation
and oxidative stress could play a central and crucial role in
the onset of post-cardiac arrest syndrome. Even though
supported by a large amount of experimental data, clinical
investigation of these phenomena after CA is lacking.
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Limitations of in vivo analytical indexes may explain, to
some extent, this knowledge gap, with issues to translate
markers from bench (experimental studies) to bedside
(clinical scenario).
While markers of inflammation (C-reactive protein
(CRP), procalcitonin (PCT)) have assumed importance as
biomarkers in critical care, their interpretations have been
questioned after CA [4]. Moreover, markers of oxidative
stress investigated in acute illness suggest disappointing
results [5,6].
Meanwhile, translational research has highlighted the
major role of thioredoxin (TRX) in physiological and
pathological conditions. This ubiquitous, 12 kDa intracel-
lular redox-active thiol protein is increased and released
during inflammation and oxidative stress. Indeed, TRX,
with its redox-active disulfide/dithiol site acting as a pro-
tein disulfide-reducing system, is a major intracellular
redox regulatory molecule scavenging reactive oxygen spe-
cies. TRX also regulates inflammation, cell signaling,
growth, and apoptosis [7,8]. Intracellular TRX is released
from cells on oxidative stress, leading to high extracellular
levels in numerous situations relevant to critical care,
including: severe burn injury [9], acute lung injury [10],
and in particular, ischemia-reperfusion injury, heart dis-
ease and sepsis [11-14].
To date, neither animal nor human studies have mea-
sured plasma concentrations of TRX after CA. Thus, this
study was designed to further explore the biological
storm occurring after CA. We hypothesized that TRX is
increased after CA, and that the magnitude of the
increase is linked with clinical course. Thus, we first mea-
sured TRX levels following CA and second, determined
associations between TRX levels and markers of severity
of post-cardiac arrest syndrome and clinical outcomes.
Materials and methods
Study setting and population
All consecutive patients over 18 admitted to our 24-bed
medical ICU between July 2006 and March 2008 after a
successfully resuscitated CA were eligible. We retrospec-
tively reviewed all medical records and data from our pro-
spectively acquired ICU database, in which all CA
survivors’ characteristics are registered according to the
Utstein style [15]. The following data were extracted pro-
spectively for each patient: demographic data, clinical
parameters, cause of CA, “no-flow” and “low-flow” period
(respectively, time from collapse to basic life support and
time from basic life support to return of spontaneous cir-
culation), initial rhythm, Simplified Acute Physiology
Score II (SAPS II) and Sequential Organ Failure Assess-
ment (SOFA) scores, hypothermia management, biological
parameters and ICU mortality. Post-resuscitation shock
was defined as the need for vasoconstrictive drug
(epinephrine or norepinephrine) infusion lasting more
than 6 hours despite adequate fluid loading. Patient man-
agement was strictly standardized [2]. When employed,
hypothermia was started immediately at ICU admission
using external cooling by forced cold air cooling during
the first 24 hours in order to obtain a target temperature
between 32°C and 34°C. Sedation using adjusted doses of
midazolam and morphine or fentanyl, and neuromuscular
blocking agent infusion during therapeutic hypothermia,
were applied. In the absence of shock or complications,
sedation was interrupted at the end of the hypothermia
period. Normothermia between 37°C and 37.5°C was then
achieved using passive rewarming at the targeted rate of
0.3°C/hour and maintained during the next 24 hours.
Patients with neither admission nor day 1 serum sample
were excluded. Part of the cohort was previously studied
to investigate PCT levels for the diagnosis of early onset
pneumonia after CA; however, patients who died within
the first 24 hours, with an infection prior to CA, or with
an extra-pulmonary infection developing within 5 days fol-
lowing admission had been excluded [4]. The study was
approved by our local Cochin University Hospital institu-
tional review board. Written consent was waived for this
study since TRX dosages did not require specific or addi-
tional blood drawing. Informed assessment was obtained
from all patients or next of kin.
Blood sampling
All TRX measurements were performed in April 2010 by
the same investigator (DB) by using blood samples
collected at admission, day 1 (D1), day 2 (D2) and day
3 (D3). These samples were initially centrifuged and stored
at -80°C within 4 hours, as approved by our local institu-
tional review board, as part of a serum collection.
Measurements of TRX were performed in duplicate sam-
ples with a commercially available sensitive enzyme-linked
immunosorbent assay (Redox Biosciences, Kyoto, Japan).
Patients exhibiting hemolysis were excluded due to the
high intracellular concentration of TRX, which will bias
assessment [7]. Plasma levels of TRX were also determined
in 30 healthy volunteers in stable condition at rest
(checked for the absence of chronic or acute illness by
questionnaire and medical examination). Analyses of CRP
were performed with a fully automated immunoturbidi-
metric assay (CRPLX, Modular PP™, Roche Diagnostics,
Mannheim, Germany). PCT concentrations were quanti-
fied with an immunofluorimetric assay (PCT sensitive,
Kryptor™, Brahms, Berlin, Germany).
Thiol determinations (expressed as μmol/L) were based
on the thiol/disulfide reaction of thiol and Ellman’s reagent
(5,5’-dithiobis(2-nitrobenzoic acid) DTNB). Fifty microli-
ters of the sample mixed with 1 ml 0.1 M Tris, 10 mM
EDTA pH 8.2, constituting the blank reaction, was assessed
at 412 nm (UVIKON, Kontron Instruments, Milan, Italy).
The addition of 40 μl 10 mM DTNB in methanol triggered
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the reaction and absorption at 412 nm was measured after
stable colour formation (1 to 3 min). The concentrations of
thiol groups were calculated using a molar extinction coef-
ficient of 13,600 M-1 cm-1.
Advanced oxidation protein products (AOPP) were
quantified as follows: 200 μl of serum diluted 1:5 in phos-
phate-buffered saline was placed into each well of a
96-well microtiter plate and added 20 μl of acetic acid to
each well. For the standards, we added 10 μl of 1.16 M
potassium iodide (Sigma-Aldrich, St Louis, MO, USA) to
200 μl of chloramine-T solution (0 to 100 μmol/l) (Sigma-
Aldrich, St Louis, MO, USA) in a well and then added 20
μl of acetic acid. The absorbance of the reaction mixture
was immediately read at 340 nm against a blank consisting
of 200 μl of phosphate-buffered saline, 10 μl of 1.16 M
potassium iodide, and 20 μl of acetic acid. AOPP concen-
trations are expressed as micromoles/liter of chloramine-T
equivalents.
Statistical analysis
Continuous variables were expressed as medians (with
interquartile range) and qualitative variables were reported
as count and proportions, unless specified otherwise. Sta-
tistical analysis compared ICU survivors and non-survivor
patients with nonparametric tests, as appropriate: continu-
ous variables with the Wilcoxon rank sum test; categorical
variables with the c2 test. Statistical significance was
defined as P < 0.05. Correlation was performed with the
Spearman test. Receiver-operated characteristic (ROC)
curves were performed to assess the ability of TRX con-
centrations to predict ICU death. Results were expressed
with area under the curve (AUC) and 95% confidence
interval. Analyses were performed with Stata 7.0 software
(StataCorp., College Station, TX, USA).
Results
During the 20-month study period, 245 patients were
admitted for a successfully resuscitated CA. After
excluding 59 patients with neither sample at admission
nor D1 and 10 patients with hemolytic blood samples,
we enrolled 176 consecutive patients in the final
analysis.
Cohort had a median age of 60 years (48 to 73) and 116
patients were men. Characteristics of CA were: ‘no-flow’
duration 5 (0 to 10) min, ‘low-flow’ duration 15 (8 to 25)
min, initial shockable rhythm n = 71 (41%), and cardiac
etiology n = 93 (53%). Non-cardiac causes were respiratory
(n = 39), neurological (n = 9) and miscellaneous (n = 35).
Severity of the population was highlighted by SAPS II
score of 68 (60 to 81) and admission SOFA score of 9
(6 to 12). Post-resuscitation shock occurred in 131 patients
(74%); 152 patients (89%) were treated with therapeutic
hypothermia. ICU mortality rate reached 61% (107
patients), whereas most of the survivors were Cerebral
Performance Category 1 or 2 (n = 64). Table 1 reports the
main characteristics of ICU survivors and non-survivors.
TRX concentration was 10.7 ng/mL (9.1 to 20.9) in
healthy volunteers (14 male, age 49 (39 to 54)). In our
patient cohort, median serum TRX values in ICU survivors
and non-survivors were respectively (Figure 1): 22 ng/mL
(7.8 to 77) vs. 72.4 (21.9 to 117.9) at admission (P < 0.001),
5.9 (3.5 to 25.5) vs. 23.2 (5.8 to 81.4) at D1 (P = 0.003),
10.8 (3.6 to 50.8) vs. 11.7 (4.5 to 66.4) at D2 (P = 0.22), and
16.7 (5.3 to 68.3) vs. 17 (4.3 to 62.9) at D3 (P = 0.96). The
areas under the ROC curves of TRX that discriminates sur-
vivors and non-survivors were: 0.66 (0.57 to 0.74) at admis-
sion, 0.65 (0.55 to 0.74) at D1, 0.56 (0.45 to 0.67) at D2 and
0.5 (0.38 to 0.62) at D3 (Figure 2).
When timing of death was considered, patients dying
within 24 hours (n = 17) had higher admission TRX levels
(118.6 ng/mL (94.8 to 280)) compared with cases of late
death or survival (respectively, 50.8 (13.9 to 95.7) and 22
(7.8 to 77), P < 0.001); area under ROC curve to predict
early death was 0.84 (0.76 to 0.91) (Figure 3). Refractory
shock was the cause of 88% of these early deaths.
Admission TRX correlated significantly with ‘low-flow’
duration (r = 0.24, P = 0.003), SOFA score (r = 0.27, P <
0.001), and admission arterial lactate concentration (r =
0.38, P < 0.001), but was not associated with ‘no-flow’
duration (r = 0.07, P = 0.39) or SAPS II score (r = 0.04,
P = 0.6). TRX levels and admission arterial pO2 correlated,
negatively (r = -0.17, P = 0.03).
Finally, patients experiencing CA due to a cardiac etiol-
ogy exhibited lower levels of TRX at admission than in
cases of extra-cardiac cause (46 ng/mL (11 to 104) vs. 68
(42 to 137), P = 0.01); similarly, patients with shockable
rhythm had lower admission TRX concentrations (16.5
(6.5 to 73.7) vs. 74 (27 to 132) than in cases of non-
shockable rhythm).
Routinely available inflammation biomarkers, CRP and
PCT, were also measured and thiol group formation and
AOPP quantified. Non-survivors exhibited higher CRP
levels at admission and at D1, whereas their PCT concen-
trations were higher from admission to D3. Conversely,
AOPP and thiol concentrations did not differ irrespective
of outcome (Table 2).
Discussion
In a large cohort of CA patients, we assessed the levels of
plasma TRX and found that very high levels occurred after
CA, with an early peak and subsequent decrease over
3 days; highest levels were associated with worst outcome.
To our knowledge, this is the first study evaluating the
potential usefulness of TRX determination for assessment
of both pathophysiology and severity after CA.
The pathophysiology of post-cardiac arrest syndrome is
dominated by a global ischemia-reperfusion phenomenon
and non-specific activation of the systemic inflammatory
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response [2]. During the ‘no-flow’ phase of CA, reduced
oxygen supply leads quickly to cellular damage. Reperfu-
sion (’low-flow’ phase of CA), generates a burst of radical
oxygen species production [3,16-18]. A number of animal
studies have explored the role of radical oxygen species
in organ damage after CA [19,20]. Other studies revealed
that oxidative stress increased quickly after CA, peaked
during early reperfusion and subsided rapidly, suggesting
that oxidant injury contributes widely to the lesions
observed after CA [21,22]. In particular, the oxidative stress
status during CA may inactivate myocardial enzymes and
thereby cause ischemic derangements of myocardial meta-
bolism. Similar features in humans were only recently
shown in a study in which plasma of out-of-hospital CA
Figure 1 Serum thioredoxin (TRX) levels on admission, then 1, 2 and 3 days after cardiac arrest, according to the ICU survival. White
boxes represent ICU survivors, grey boxes represent non-survivor patients. The median is shown by the horizontal line within the box. The
values between the lower and upper quartiles (25th to 75th centiles) are within the box.
Table 1 Baseline admission characteristics and outcome of ICU survivors and non-survivors.
All patients
(n = 176)
Survivors
(n = 69)
Non-survivors
(n = 107)
P
Age (year) 60 (48-73) 57 (46-68) 60 (49-74) 0.18
No-flow duration (min) 5 (0-10) 2 (0-5) 5 (1-10) 0.004
Low-flow duration (min) 15 (8-25) 10 (5-16) 20 (10-26) < 0.001
Shockable rhythm 71 (41) 47 (68) 24 (22) < 0.001
Cardiac etiology 93 (53) 44 (68) 47 (44) 0.02
SAPS II score 68 (60-81) 68 (61-82) 67 (58-81) 0.55
Admission SOFA score 9 (6-12) 7 (5-10) 11 (8-13) < 0.001
Admission temperature (°C) 35.4 (34.7-36.6) 35.8 (34.8-36.5) 35.3 (34.7-36.9) 0.65
Therapeutic hypothermia 152 (89) 65 (94) 87 (81) 0.02
Post-resuscitation shock 131 (74) 49 (71) 82 (76) 0.4
Data are expressed as median (with interquartile range) or absolute value (%). Statistical analysis is performed between survivors and non-survivors. SAPS II,
Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.
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Figure 2 Receiver-operated characteristic (ROC) curves comparing the ability of thioredoxin (TRX) concentrations to predict ICU death
at admission, day 1, day 2 and day 3.
Figure 3 Receiver-operated characteristic (ROC) curve determining the ability of thioredoxin (TRX) concentration to predict death
within 24 hours.
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survivors induced acute and major endothelial toxicity,
attributable to an acute pro-oxidant state occurring within
the cells, as shown by a significant decrease of the main
antioxidant defences. Another striking finding was that
plasma toxicity lasting for more than 3 days after CA [23].
With respect to the inflammatory response associated
with CA, a wide panel of proteins and biomarkers investi-
gated in several animal models and human cohorts sug-
gests that a major inflammatory syndrome occurs after
CA [2,24,25]. Consequently, post-cardiac arrest syndrome
was defined as a ‘sepsis-like syndrome’, with clinical, bio-
chemical and hematological features that are very similar
to those observed during severe sepsis, and increased
levels of pro- and anti-inflammatory cytokines comparable
to the variations described during septic shock [24,26].
Moreover, disseminated vascular endothelial damage also
suggests that ischemia-reperfusion associated with CA
evolves toward systemic inflammation with overproduc-
tion of cytokines, complement activation, synthesis of ara-
chidonic acid metabolites, expression of leukocyte
adhesion molecules and activation and chemotaxis of
polymorphonuclear neutrophils contributing to the
inflammatory response [2].
TRX concentrations in healthy volunteers were similar
in our study to those previously reported by others (15 to
25 ng/mL). Also, increased levels of TRX of 36.1 ng/mL
in patients with acute lung injury [10] and up to 161.6
ng/mL in patients with sepsis [14] are similar to the levels
and magnitude of increase we found in patients following
CA. TRX was also found to be elevated after cardiopul-
monary bypass or heart failure, two clinical situations
that combine great inflammation and circulatory distur-
bances [27,28]. Moreover, as has been previously
reported for patients with sepsis [14] or meningococcal
septic shock [11], we found that TRX levels were signifi-
cantly higher in non-survivors than in survivors, even if
ability to predict ICU death was not robust. In addition,
patients dying within 24 hours exhibited the highest
levels of TRX, with admission concentration carrying a
very good ability to predict early death.
Our findings suggest that patients suffer from major oxi-
dative stress and inflammation during post-cardiac arrest
syndrome, which cannot be counteracted by increased
TRX production. Others have suggested that prolonged
oxidative stress in patients with coronary risk factors
wastes the serum antioxidant pool such as vitamin C and
that serum TRX is recruited to compensate [29]. That our
data show highest levels associated with worse outcome
following CA is perhaps suggestive of the severity of oxi-
dative stress associated with the condition. These findings
confirm and broaden the data of post-cardiac arrest syn-
drome pathophysiology, supporting the hypothesis that
Table 2 Plasma concentrations of thiol, advanced oxidation protein product (AOPP), C-reactive protein (CRP) and
procalcitonin (PCT) according to the outcome.
Survival
n = 69
Early death
(< 24 h)
n = 17
Late death
(> 24 h)
n = 90
P
Thiols (μmol/L)
Admission 275 (223-316) 251 (193-358) 247 (193-299) 0.31
Day 1 310 (239-358) 299 (219-360) 0.97
Day 2 272 (221-319) 267 (228-331) 0.64
Day 3 240 (191-273) 244 (210-292) 0.23
AOPP (μmol/L)
Admission 36.8 (22.2-64.7) 42 (25.3-78.6) 40.4 (21.7-59.5) 0.87
Day 1 27.9 (14.7-54.1) 37 (23.4-60.4) 0.11
Day 2 32.4 (19.9-65.8) 36.5 (25.8-62.1) 0.43
Day 3 28.4 (22.3-48) 28.9 (28.9-58.6) 0.98
CRP (mg/mL)
Admission 2.15 (1-6.5) 4.6 (1-28.9) 3.95 (1.3-32.7) 0.05
Day 1 42.1 (18-1-79.6) 66.2 (19.9-135.8) 0.02
Day 2 137.4 (94.9-180) 158 (84-198) 0.34
Day 3 176 (102-199) 170 (79.9-217) 0.94
PCT (ng/mL)
Admission 0.18 (0.1-0.67) 0.55 (0.23-2.2) 0.66 (0.18-3.74) 0.0004
Day 1 1 (0.25-6.04) 6.38 (1.18-29.7) 0.0001
Day 2 0.82 (0.22-4.83) 4.54 (1.28-29.2) 0.0001
Day 3 0.96 (0.28-3.45) 5.8 (1.08-19.6) 0.0002
Data are expressed as median, with interquartile range. Statistical analysis is performed between survivors and non-survivors.
Mongardon et al. Critical Care 2013, 17:R18
http://ccforum.com/content/17/1/R18
Page 6 of 10
oxidative stress and inflammatory insults are much more
marked in the most severe patients and contribute largely
to the high initial mortality. Likewise, when focusing on
the cause of CA, cardiac etiologies had lower TRX levels.
This is in line with the overall better prognosis of CA of
coronary origin [30].
When focusing on disease severity, TRX concentrations
were correlated to admission arterial lactate levels, a biolo-
gical parameter that is constantly associated with unfavor-
able outcome [31]. We also found a strong association
between low-flow duration and TRX levels, whereas this
was not observed with the no-flow duration. This illus-
trates the pathophysiology of the ischemia reperfusion
injury, with a major reactive oxygen species production
during the reperfusion phase [16,17,32]. This is also con-
sistent with the well-known observation that the severity
of the post-cardiac arrest syndrome is much more driven
by the low-flow duration [33]. Finally, the absence of cor-
relation with SAPS II, by contrast with association with
SOFA score, could be explained by the fact that SOFA
score describes strictly organ failures [34]. Conversely,
SAPS II score takes into account not only medical condi-
tion, but also underlying comorbidities [35].
Perhaps, surprisingly, we observed that TRX levels
decreased within of short range of time. As inflammatory
and pro-oxidant states are known to persist after CA, this
finding might suggest that TRX half-life is relatively short,
or that release is minimized after the initial insult, or that
other serum antioxidants have been replenished. This con-
trasts with sustained levels of other biomarkers such as
PCT, which remain elevated 3 days after CA [4]. The dif-
ference in kinetic profile is intriguing and warrants further
investigation.
The negative correlation between plasma TRX levels
and arterial pO2 at admission that we found in our study
advocates against a role of hyperoxia in the onset of oxi-
dative stress. There is a great controversy surrounding
hyperoxia after CA resuscitation, with some experimental
data suggesting that hyperoxia might increase oxidative
stress. While animal models were inconclusive [36], a
human study suggested that hyperoxia was independently
associated with in-hospital mortality, as compared with
hypoxemia or normoxia [37]. However, the latter finding
was refuted by both a study, in which this association did
not appear in a large cohort, with adjustment on severity
scores [36] and also our findings in the current work.
Nevertheless, further studies are required to elucidate
this hot topic [38,39].
TRX reflects both inflammation and oxidative stress,
two major determinants of severity of post-cardiac arrest
syndrome and could be considered as a potential marker
of the global insult. However, the clinical utility of TRX
has to be further established [40], as does the mechanis-
tic explanation linking increased TRX levels with the
biological disorders occurring after CA and post-cardiac
arrest syndrome. TRX is elevated on admission, whereas
vasoplegia and myocardial dysfunction typically begin a
few hours after CA. In the future, utilizing biomarkers of
inflammation and oxidative stress might allow tailoring
therapeutic interventions that modulate inflammation or
oxidative stress such as high volume hemofiltration [41]
or steroids administration [42].
Besides its role of biomarker, TRX could be a future
therapeutic target. Hofer et al. demonstrated, in an
experimental model of cecal ligature and puncture, that
neutralization of endogenous TRX was deleterious for
septic mice survival, whereas treatment with recombinant
TRX markedly enhanced their survival [14]. To date, no
human data of such protective effects of TRX is available.
However, major hope arose in the field of resuscitation
after the use of coenzyme Q10, a mitochondrial enzyme
playing a key role in antioxidant defense. In 49 patients
experiencing CA, exogenous administration of this anti-
oxidant improved both survival and neurological out-
come [43]. Further investigations are required to
determine the place of TRX modulation in the armamen-
tarium of critical care therapeutics.
Although these data suggest that TRX could reflect a
response to inflammation and oxidative stress, the func-
tional consequences of high levels of TRX are not com-
pletely understood. The potential biological significance
of TRX upregulation can be inferred from experimental
studies, which support a role as an antioxidant and anti-
inflammatory protein, through modulation of both heme
oxygenase-1 and NADPH oxidase-mediated generation
of superoxide anion. Extracellular TRX has been reported
to reduce interleukin 1-beta expression by monocyte-
macrophages in inflammatory conditions [7]. In addition,
circulating TRX suppresses neutrophil chemotaxis [44].
More recently, it has been suggested that the anti-inflam-
matory mechanisms of TRX could be mediated, at least
in part, by migration inhibitory factor (MIF) downregula-
tion [45]. However, in septic conditions, TRX and MIF
plasma levels showed a strong correlation, suggesting
that pro- and anti-inflammatory agents are balanced to
maintain homeostasis [46].
In the present study, we confirm the limited interest of
AOPP measurement and thiol content determination in
acute setting, at least after CA, despite their place in
experimental conditions [5,6]. On the contrary, high CRP
and PCT levels are consistent with previous findings sug-
gesting the overwhelming impact of systemic inflamma-
tion [4]. Overall, these results enhance the value of TRX
after CA.
Despite the large number of post-CA patients enrolled,
some limitations of this study need consideration. First,
we considered a retrospective single-institution cohort.
However, all analyzed data were prospectively collected,
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and medical management was homogeneous. Second,
this is a merely observational study, allowing only asso-
ciation rather than causation conclusions. Third, the uti-
lity of TRX to predict death was evaluated as a single
parameter, without combination of TRX level to clinical
or biological data that may have improved the overall
prognosis value. Fourth, measurement of other oxidative
stress parameters, like MIF or manganese superoxide dis-
mutase (MnSOD), or main inflammatory cytokines
would have provided further mechanistic tracks. Simi-
larly, determination of the TRX interacting protein
(TXNIP) could give valuable data to help explain the
TRX kinetics after CA. However, TXNIP is an intracellu-
lar protein that cannot be routinely measured in serum
samples. Fifth, CA has the particularity of exhibiting two
main causes of ICU death, that is, shock and neurological
damage with subsequent care withdrawal. As inflamma-
tion and oxidative stress are expected to be greater in
case of shock, subanalysis focused on this last group.
Finally, the vast majority of patients underwent therapeu-
tic hypothermia. If the relationship between inflamma-
tory cytokines or biomarkers and effect of therapeutic
hypothermia is controversial [4,25], the influence of
hypothermia on TRX is as yet, unknown. As the vast
majority of our patients were treated by hypothermia, we
could not perform a meaningful analysis of the impact of
temperature on TRX levels. Similarly, there is no data
about clearance of TRX during renal replacement ther-
apy, which is widely applied in post-cardiac arrest survi-
vors. To note, we report a high proportion of patients
experiencing post-resuscitation shock. This is related to
the study design, including all consecutive patients and
in particular those dying within 24 hours. These most
severe patients are generally excluded from clinical stu-
dies. Nonetheless, it is likely to be the group of patients
of the most significant clinical interest.
Conclusions
In patients successfully resuscitated from CA, serum TRX
levels measured during the first 3 days were higher in ICU
non-survivors, and were dramatically greater in patients
dying early from circulatory failure. Besides assessing
severity and outcome, such a biomarker offers interesting
perspectives in the comprehension and management of
post-cardiac arrest syndrome.
Key messages
• Thioredoxin (TRX), a surrogate global marker of
inflammation and oxidative stress, was largely
increased during post-cardiac arrest syndrome.
• The highest values were found in the most severe
patients.
• Cardiac arrest with cardiac etiology exhibited lower
levels of TRX than in cases of extra-cardiac cause.
• Admission TRX levels were significantly correlated
with other pertinent severity markers, like ‘low-flow’
duration, SOFA score, and arterial lactate concen-
tration.
• No correlation was found between TRX levels and
admission arterial pO2, arguing against a potential
role of hyperoxia after cardiac arrest.
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